Compare MORN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | TVTX |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | 497 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.3B |
| IPO Year | 2004 | 2013 |
| Metric | MORN | TVTX |
|---|---|---|
| Price | $166.31 | $56.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $256.50 | $40.62 |
| AVG Volume (30 Days) | 422.5K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | 3.38 | ★ 92.89 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,445,500,000.00 | N/A |
| Revenue This Year | $9.14 | $44.76 |
| Revenue Next Year | $7.23 | $35.51 |
| P/E Ratio | $60.75 | ★ N/A |
| Revenue Growth | ★ 7.49 | N/A |
| 52 Week Low | $141.49 | $15.03 |
| 52 Week High | $295.77 | $60.10 |
| Indicator | MORN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 67.02 |
| Support Level | $161.01 | $41.75 |
| Resistance Level | $188.92 | $60.10 |
| Average True Range (ATR) | 7.14 | 2.09 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 66.54 | 71.40 |
Morningstar Inc is a provider of independent investment insights to financial advisers, asset managers, and investors. It provides data and research insights on various investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time market data. The company has five reportable segments: Morningstar Direct Platform, PitchBook, Morningstar Credit, Morningstar Wealth, and Morningstar Retirement. Maximum revenue is derived from the Morningstar Direct Platform, which provides investors with comprehensive data, research, insights, and investment analysis through product areas such as Morningstar Data, Morningstar Direct, and Morningstar Advisor Workstation. Geographically, it generates maximum revenue from the USA.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.